CompanyShort-termNeutralDays to weeksBenzingaMRK

European Commission Withdraws EU Marketing Authorisation For Zinplava At Merck Sharp & Dohme B.V.’s Request After Permanent Discontinuation For Commercial Reasons

Reviewed by ClearTape · Source: Benzinga

Key takeaways

Merck is discontinuing Zinplava, ending its EU presence after nine years of sales.
Zinplava approved 18 January 2017
Unlimited validity granted 2021
Indication extended to children December 2023

What happened

The European Commission pulled the EU marketing licence for Merck’s drug Zinplava (bezlotoxumab) after the company said it would stop selling the product for commercial reasons.

Why it matters

Zinplava had been a key treatment for preventing repeat Clostridium difficile infections in adults and, since 2023, in children. Its removal means patients and clinicians lose a proven option and could shift demand to other therapies.

Short-term and longer-term

Short-term. Merck’s exit may prompt a short‑term dip in the stock as investors reassess the company’s drug pipeline.

Longer-term. Over the next few months, the discontinuation could alter Merck’s long‑term strategy in the infectious disease space, potentially reallocating resources to other growth areas.

ClearTape summarizes context in-app. For the full publisher article, use Read original source above.